|
DE10347710B4
(de)
|
2003-10-14 |
2006-03-30 |
Johannes-Gutenberg-Universität Mainz |
Rekombinante Impfstoffe und deren Verwendung
|
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
|
US9732131B2
(en)
|
2006-02-27 |
2017-08-15 |
Calviri, Inc. |
Identification and use of novopeptides for the treatment of cancer
|
|
CA2772076A1
(en)
|
2009-08-24 |
2011-03-10 |
Baylor College Of Medicine |
Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
|
|
US9115402B2
(en)
|
2010-05-14 |
2015-08-25 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods of identifying tumor specific neoantigens
|
|
LT2714071T
(lt)
*
|
2011-05-24 |
2019-10-10 |
Biontech Rna Pharmaceuticals Gmbh |
Individualizuotos vakcinos nuo vėžio
|
|
SI2714071T1
(sl)
*
|
2011-05-24 |
2019-11-29 |
Biontech Rna Pharmaceuticals Gmbh |
Individualizirana cepiva proti raku
|
|
EP2757153B1
(en)
*
|
2011-08-02 |
2019-07-03 |
The University of Tokyo |
Method for assessing myelodysplastic syndrome or myeloid tumor predisposition, polypeptide and antibody therefor, and candidate screening method for therapeutic drug or prophylactic drug therefor
|
|
US20130164746A1
(en)
*
|
2011-09-29 |
2013-06-27 |
Davide Rossi |
Mutations in SF3B1 and Chronic Lymphocytic Leukemia
|
|
WO2013086464A1
(en)
*
|
2011-12-07 |
2013-06-13 |
The Broad Institute, Inc. |
Markers associated with chronic lymphocytic leukemia prognosis and progression
|
|
GB201121308D0
(en)
|
2011-12-12 |
2012-01-25 |
Cell Medica Ltd |
Process
|
|
EP2812431B1
(en)
|
2012-02-09 |
2019-07-17 |
Baylor College Of Medicine |
Pepmixes to generate multiviral ctls with broad specificity
|
|
WO2013143555A1
(en)
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
|
WO2013177593A2
(en)
|
2012-05-25 |
2013-11-28 |
Phosimmune, Inc. |
Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies
|
|
MX364370B
(es)
*
|
2012-07-12 |
2019-04-24 |
Persimmune Inc |
Vacunas contra el cancer personalizadas y terapias de celulas inmunes adoptivas.
|
|
GB201214007D0
(en)
*
|
2012-08-07 |
2012-09-19 |
Scancell Ltd |
Anti-tumour immune responses to modified self-epitopes
|
|
WO2014036562A2
(en)
*
|
2012-08-31 |
2014-03-06 |
University Of Virginia Patent Foundation |
Target peptides for immunotherapy and diagnostics
|
|
HK1212236A1
(en)
|
2012-09-05 |
2016-06-10 |
University Of Virginia Patent Foundation |
Target peptides for colorectal cancer therapy and diagnostics
|
|
US10501801B2
(en)
|
2012-09-28 |
2019-12-10 |
University Of Connecticut |
Identification of tumor-protective epitopes for the treatment of cancers
|
|
AU2013351542B2
(en)
|
2012-11-28 |
2018-08-09 |
BioNTech SE |
Individualized vaccines for cancer
|
|
GB2508414A
(en)
*
|
2012-11-30 |
2014-06-04 |
Max Delbrueck Centrum |
Tumour specific T cell receptors (TCRs)
|
|
EP3578200A1
(en)
|
2013-02-22 |
2019-12-11 |
CureVac AG |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
SG11201506052PA
(en)
|
2013-02-22 |
2015-09-29 |
Curevac Gmbh |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
MX376790B
(es)
|
2013-03-14 |
2025-03-07 |
Univ Johns Hopkins |
Células presentadoras de antígeno artificiales de nanoescala.
|
|
AU2014251207B2
(en)
*
|
2013-04-07 |
2019-06-13 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for personalized neoplasia vaccines
|
|
WO2014180490A1
(en)
|
2013-05-10 |
2014-11-13 |
Biontech Ag |
Predicting immunogenicity of t cell epitopes
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
|
JP6740127B2
(ja)
*
|
2013-12-06 |
2020-08-12 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
新生物ワクチン用製剤
|
|
JP7060324B2
(ja)
*
|
2013-12-20 |
2022-04-26 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
ネオ抗原ワクチンによる併用療法
|
|
SG11201605432RA
(en)
*
|
2014-01-02 |
2016-07-28 |
Sloan Kettering Inst Cancer |
Determinants of cancer response to immunotherapy
|
|
CA2935878C
(en)
|
2014-03-12 |
2023-05-02 |
Curevac Ag |
Combination of vaccination and ox40 agonists
|
|
EP3137100B1
(en)
|
2014-04-15 |
2023-12-20 |
University Of Virginia Patent Foundation |
Isolated t cell receptors and methods of use therefor
|
|
US20170224799A1
(en)
*
|
2014-09-10 |
2017-08-10 |
The University Of Connecticut |
Identification of immunologically protective neo-epitopes for the treatment of cancers
|
|
EP3194970B1
(en)
*
|
2014-09-10 |
2021-07-28 |
F. Hoffmann-La Roche AG |
Immunogenic mutant peptide screening platform
|
|
US11338026B2
(en)
|
2014-09-10 |
2022-05-24 |
The University Of Connecticut |
Identification of immunologically protective neo-epitopes for the treatment of cancers
|
|
CA2961179A1
(en)
*
|
2014-09-14 |
2016-03-17 |
Washington University |
Personalized cancer vaccines and methods therefor
|
|
SG11201702191YA
(en)
*
|
2014-09-17 |
2017-04-27 |
Univ Johns Hopkins |
Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells
|
|
PL3193917T3
(pl)
*
|
2014-09-17 |
2022-01-17 |
Io Biotech Aps |
Kompozycje szczepionek zawierające 2,3-dioksygenazę tryptofanową lub jej fragmenty
|
|
WO2016045732A1
(en)
|
2014-09-25 |
2016-03-31 |
Biontech Rna Pharmaceuticals Gmbh |
Stable formulations of lipids and liposomes
|
|
CN107075479A
(zh)
|
2014-10-02 |
2017-08-18 |
美国卫生和人力服务部 |
分离对癌症特异性突变具有抗原特异性的t细胞的方法
|
|
CA2964155A1
(en)
*
|
2014-10-10 |
2016-04-14 |
Idera Pharmaceuticals, Inc. |
Treatment of cancer using tlr9 agonist with checkpoint inhibitors
|
|
MA40737A
(fr)
|
2014-11-21 |
2017-07-04 |
Memorial Sloan Kettering Cancer Center |
Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
|
|
EP3234130B1
(en)
|
2014-12-19 |
2020-11-25 |
The Broad Institute, Inc. |
Methods for profiling the t-cell- receptor repertoire
|
|
US10975442B2
(en)
|
2014-12-19 |
2021-04-13 |
Massachusetts Institute Of Technology |
Molecular biomarkers for cancer immunotherapy
|
|
WO2016128060A1
(en)
*
|
2015-02-12 |
2016-08-18 |
Biontech Ag |
Predicting t cell epitopes useful for vaccination
|
|
AU2016238290B9
(en)
|
2015-03-25 |
2019-06-13 |
The Regents Of The University Of Michigan |
Compositions and methods for delivery of biomacromolecule agents
|
|
US20190099475A1
(en)
|
2015-04-08 |
2019-04-04 |
Nantomics, Llc |
Cancer neoepitopes
|
|
CA3172682A1
(en)
*
|
2015-04-23 |
2016-10-27 |
Nantomics, Llc |
Cancer neoepitopes
|
|
GB201507030D0
(en)
|
2015-04-24 |
2015-06-10 |
Immatics Biotechnologies Gmbh |
Immunotherapy against lung cancers, in particular NSCLC
|
|
MX381241B
(es)
*
|
2015-04-27 |
2025-03-12 |
Cancer Research Tech Ltd |
Composición de células t para usarse en el tratamiento del cáncer.
|
|
US10544392B2
(en)
|
2015-05-01 |
2020-01-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
|
|
EP3294324A1
(en)
|
2015-05-13 |
2018-03-21 |
Agenus Inc. |
Vaccines for treatment and prevention of cancer
|
|
JP6913032B2
(ja)
*
|
2015-05-20 |
2021-08-04 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
共通ネオ抗原
|
|
TW202241500A
(zh)
*
|
2015-06-09 |
2022-11-01 |
美商博德研究所有限公司 |
用於贅瘤疫苗之調配物及其製備方法
|
|
US10563266B2
(en)
|
2015-07-14 |
2020-02-18 |
Personal Genome Diagnostics Inc. |
Neoantigen treatment prioritization using multivariate analysis based on: HLA genotype, self-similarity, similarity to known antigens, antigen expression levels and mutant allele frequency
|
|
EP3328394A4
(en)
|
2015-07-30 |
2019-03-13 |
ModernaTX, Inc. |
CONCATEMEE peptide epitope RNAs
|
|
GB201516047D0
(en)
*
|
2015-09-10 |
2015-10-28 |
Cancer Rec Tech Ltd |
Method
|
|
US11167024B2
(en)
*
|
2015-09-18 |
2021-11-09 |
Baylor College Of Medicine |
Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
|
|
WO2017059902A1
(en)
|
2015-10-07 |
2017-04-13 |
Biontech Rna Pharmaceuticals Gmbh |
3' utr sequences for stabilization of rna
|
|
KR20180087246A
(ko)
*
|
2015-10-12 |
2018-08-01 |
난토믹스, 엘엘씨 |
네오에피토프의 반복적 발견 및 이에 대한 적응성 면역치료 및 방법
|
|
WO2017066290A1
(en)
*
|
2015-10-12 |
2017-04-20 |
Nantomics, Llc |
Viral neoepitopes and uses thereof
|
|
AU2016339035A1
(en)
*
|
2015-10-12 |
2018-05-10 |
Nantomics, Llc |
Systems, compositions, and methods for discovery of MSI and neoepitopes that predict sensitivity to checkpoint inhibitors
|
|
CN108601820A
(zh)
*
|
2015-10-12 |
2018-09-28 |
南托米克斯有限责任公司 |
用于病毒癌症新表位的组合物和方法
|
|
EP3364949A4
(en)
*
|
2015-10-22 |
2019-07-31 |
ModernaTX, Inc. |
CANCER VACCINES
|
|
MX2018004838A
(es)
|
2015-11-06 |
2019-07-18 |
Ventana Med Syst Inc |
Diagnosticos representativos.
|
|
TWI733719B
(zh)
*
|
2015-12-07 |
2021-07-21 |
美商河谷控股Ｉｐ有限責任公司 |
改善的組合物及用於新表位之病毒遞送的方法及其應用
|
|
JP7114477B2
(ja)
*
|
2015-12-16 |
2022-08-08 |
グリットストーン バイオ インコーポレイテッド |
新生抗原の特定、製造、および使用
|
|
CA3048202A1
(en)
*
|
2015-12-23 |
2017-06-29 |
Moonshot Pharma Llc |
Methods for inducing an immune response by inhibition of nonsense mediated decay
|
|
JP2019505512A
(ja)
|
2016-01-08 |
2019-02-28 |
バッシボディ アクスイェ セルスカプ |
治療用抗癌ネオエピトープワクチン
|
|
US20170224796A1
(en)
|
2016-02-05 |
2017-08-10 |
Xeme Biopharma Inc. |
Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
|
|
CN108701172A
(zh)
*
|
2016-02-12 |
2018-10-23 |
南托米克斯有限责任公司 |
高通量识别患者特异性新表位作为癌症免疫疗法的治疗靶点
|
|
AU2017219901B2
(en)
*
|
2016-02-19 |
2022-07-14 |
Nant Holdings Ip, Llc |
Methods of immunogenic modulation
|
|
CN105720176A
(zh)
*
|
2016-02-19 |
2016-06-29 |
京东方科技集团股份有限公司 |
一种胶囊量子点和发光二极管、制备方法及显示装置
|
|
JP2019513021A
(ja)
*
|
2016-03-24 |
2019-05-23 |
ナントセル，インコーポレイテッド |
ネオエピトープ提示のための配列の配置および配列
|
|
WO2017177207A1
(en)
*
|
2016-04-07 |
2017-10-12 |
Bostongene, Llc |
Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
|
|
WO2017180769A1
(en)
*
|
2016-04-13 |
2017-10-19 |
Capten Therapeutics Inc. |
Small molecules for immunogenic treatment of cancer
|
|
EP3471778A4
(en)
|
2016-06-20 |
2020-02-19 |
The Regents of The University of Michigan |
COMPOSITIONS AND METHOD FOR DELIVERING BIOMACROMOLECOLIC ACTIVE SUBSTANCES
|
|
US20190247435A1
(en)
*
|
2016-06-29 |
2019-08-15 |
The Johns Hopkins University |
Neoantigens as targets for immunotherapy
|
|
AU2017295704B2
(en)
|
2016-07-13 |
2023-07-13 |
President And Fellows Of Harvard College |
Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
|
|
CA3031003A1
(en)
*
|
2016-07-20 |
2018-01-25 |
Biontech Rna Pharmaceuticals Gmbh |
Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy
|
|
AU2017305396A1
(en)
*
|
2016-08-02 |
2019-02-21 |
Nant Holdings Ip, Llc |
Transfection of dendritic cells and methods therefor
|
|
US10350280B2
(en)
|
2016-08-31 |
2019-07-16 |
Medgenome Inc. |
Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
|
|
US20190237158A1
(en)
*
|
2016-08-31 |
2019-08-01 |
Medgenome, Inc. |
Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
|
|
US10463686B2
(en)
|
2016-09-15 |
2019-11-05 |
Idera Pharmaceuticals, Inc. |
Immune modulation with TLR9 agonists for cancer treatment
|
|
EP3516045A1
(en)
*
|
2016-09-23 |
2019-07-31 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same
|
|
US20190240257A1
(en)
*
|
2016-10-13 |
2019-08-08 |
The Johns Hopkins University |
Compositions and methods for identifying functional anti-tumor t cell responses
|
|
EP4338799A3
(en)
*
|
2016-10-18 |
2024-06-05 |
Regents of the University of Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
|
US20190321481A1
(en)
|
2016-11-11 |
2019-10-24 |
Nantbio, Inc. |
Immunomodulatory compositions, processes for making the same, and methods for inhibiting cytokine storms
|
|
WO2018102613A2
(en)
|
2016-12-01 |
2018-06-07 |
Nantomics, Llc |
Tumor antigenicity processing and presentation
|
|
EP3574116A1
(en)
|
2017-01-24 |
2019-12-04 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
|
CA3052255A1
(en)
*
|
2017-02-01 |
2018-08-09 |
Modernatx, Inc. |
Rna cancer vaccines
|
|
MX2019009070A
(es)
|
2017-02-01 |
2019-10-30 |
Modernatx Inc |
Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.
|
|
EP3601536A4
(en)
*
|
2017-03-20 |
2021-01-13 |
Genocea Biosciences, Inc. |
TREATMENT PROCEDURES
|
|
WO2018183544A1
(en)
*
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Method for identification of retained intron tumor neoantigens from patient transcriptome
|
|
EP3606550A2
(en)
|
2017-04-03 |
2020-02-12 |
Neon Therapeutics, Inc. |
Protein antigens and uses thereof
|
|
JP2020515629A
(ja)
|
2017-04-04 |
2020-05-28 |
アヴィディア テクノロジーズ， インコーポレイテッド |
免疫応答を誘導するためのペプチドベースのワクチン、それらの製造方法および使用
|
|
AU2018254526B2
(en)
*
|
2017-04-19 |
2024-02-15 |
Seattle Project Corp. |
Neoantigen identification, manufacture, and use
|
|
CA3061240C
(en)
|
2017-04-24 |
2024-01-16 |
Nantcell, Inc. |
Targeted neoepitope vectors and methods therefor
|
|
KR102945203B1
(ko)
|
2017-05-08 |
2026-03-31 |
시애틀 프로젝트 코포레이션 |
알파바이러스 신생항원 벡터
|
|
EP3622068B1
(en)
|
2017-05-10 |
2024-02-28 |
The Broad Institute, Inc. |
Methods for determination of mutations in single replication events
|
|
US12226479B2
(en)
|
2017-05-11 |
2025-02-18 |
The General Hospital Corporation |
Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
|
|
EP3630131B1
(en)
*
|
2017-06-02 |
2022-08-31 |
Arizona Board of Regents on behalf of Arizona State University |
A method to create personalized canine cancer vaccines
|
|
WO2018224166A1
(en)
|
2017-06-09 |
2018-12-13 |
Biontech Rna Pharmaceuticals Gmbh |
Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
|
|
KR20240113607A
(ko)
*
|
2017-06-21 |
2024-07-22 |
트랜스진 |
개인 맞춤형 백신
|
|
WO2019014581A1
(en)
|
2017-07-14 |
2019-01-17 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
|
|
KR20200030593A
(ko)
|
2017-07-21 |
2020-03-20 |
버클리 라잇츠, 인크. |
항원 제시 합성 표면, 공유결합으로 관능화된 표면, 활성화된 t 세포, 및 이들의 용도
|
|
CN111727262A
(zh)
|
2017-07-25 |
2020-09-29 |
加州理工学院 |
胞啃介导的表位发现
|
|
WO2019036043A2
(en)
*
|
2017-08-16 |
2019-02-21 |
Medgenome Inc. |
METHOD FOR GENERATING A COCKTAIL OF PERSONALIZED ANTICANCER VACCINES FROM TUMOR DERIVED GENETIC MODIFICATIONS FOR THE TREATMENT OF CANCER
|
|
US12025615B2
(en)
|
2017-09-15 |
2024-07-02 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods of classifying response to immunotherapy for cancer
|
|
CA3076918A1
(en)
*
|
2017-10-02 |
2019-04-11 |
Curematch, Inc. |
Method of prediction of tumor-derived neo-peptide antigenicity and/or immunogenicity using mutational signature patterns
|
|
RU2020115161A
(ru)
*
|
2017-10-06 |
2021-11-08 |
Дзе Уистар Инститьют Оф Энэтоми Энд Байолоджи |
Днк моноклональных антител против ctla-4 для лечения и профилактики рака
|
|
CN111465989B
(zh)
|
2017-10-10 |
2024-06-25 |
磨石生物公司 |
使用热点进行的新抗原鉴别
|
|
CA3081479A1
(en)
*
|
2017-11-06 |
2019-05-09 |
Ludwig Institute For Cancer Research Ltd |
Method for expansion of lymphocytes
|
|
WO2019094396A1
(en)
*
|
2017-11-07 |
2019-05-16 |
Nektar Therapeutics |
Immunotherapeutic combination for treating cancer
|
|
JP7054418B2
(ja)
|
2017-11-08 |
2022-04-13 |
ビオンテック ユーエス インコーポレイテッド |
Ｔ細胞を製造する組成物及び方法
|
|
AU2018373154B2
(en)
|
2017-11-22 |
2025-08-07 |
Seattle Project Corp. |
Reducing junction epitope presentation for neoantigens
|
|
CN109682978B
(zh)
*
|
2017-11-30 |
2020-07-03 |
四川康德赛医疗科技有限公司 |
一种肿瘤突变肽mhc亲和力预测方法及其应用
|
|
TW201930340A
(zh)
|
2017-12-18 |
2019-08-01 |
美商尼恩醫療公司 |
新抗原及其用途
|
|
KR20240134250A
(ko)
|
2018-01-04 |
2024-09-06 |
아이코닉 테라퓨틱스, 인코포레이티드 |
항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법
|
|
US11573230B2
(en)
|
2018-01-26 |
2023-02-07 |
Nantcell, Inc. |
Rapid verification of virus particle production for a personalized vaccine
|
|
EP3743102A1
(en)
|
2018-01-26 |
2020-12-02 |
Nantcell, Inc. |
Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
|
|
CN108491689B
(zh)
*
|
2018-02-01 |
2019-07-09 |
杭州纽安津生物科技有限公司 |
基于转录组的肿瘤新抗原鉴定方法
|
|
IL276839B1
(en)
*
|
2018-02-27 |
2026-05-01 |
Gritstone Bio Inc |
Neoantigen identification using pan-allelic models
|
|
EP3784688A2
(en)
|
2018-04-26 |
2021-03-03 |
Agenus Inc. |
Heat shock protein-binding peptide compositions and methods of use thereof
|
|
TW202000907A
(zh)
|
2018-05-23 |
2020-01-01 |
美商葛利史東腫瘤科技公司 |
共有抗原
|
|
US12528848B2
(en)
|
2018-05-25 |
2026-01-20 |
The Wistar Institute Of Anatomy And Biology |
Tumor-specific neoantigens and methods of using the same
|
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
SG11202012653XA
(en)
|
2018-06-19 |
2021-01-28 |
Biontech Us Inc |
Neoantigens and uses thereof
|
|
CA3106567A1
(en)
|
2018-07-26 |
2020-01-30 |
Frame Pharmaceuticals B.V. |
Cancer vaccines for kidney cancer
|
|
WO2020022901A1
(en)
|
2018-07-26 |
2020-01-30 |
Frame Pharmaceuticals B.V. |
Cancer vaccines for uterine cancer
|
|
CA3106574A1
(en)
|
2018-07-26 |
2020-01-30 |
Frame Pharmaceuticals B.V. |
Arid1a, cdkn2a, kmt2b, kmt2d, tp53 and pten vaccines for cancer
|
|
EP3827262A1
(en)
|
2018-07-26 |
2021-06-02 |
Frame Pharmaceuticals B.V. |
Cancer vaccines for breast cancer
|
|
CA3106573A1
(en)
|
2018-07-26 |
2020-01-30 |
Frame Pharmaceuticals B.V. |
Cancer vaccines for colorectal cancer
|
|
WO2020022897A1
(en)
*
|
2018-07-26 |
2020-01-30 |
Frame Pharmaceuticals B.V. |
Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
|
|
CN109021062B
(zh)
*
|
2018-08-06 |
2021-08-20 |
倍而达药业（苏州）有限公司 |
一种肿瘤新抗原的筛选方法
|
|
JP7539367B2
(ja)
|
2018-08-31 |
2024-08-23 |
ガーダント ヘルス， インコーポレイテッド |
無細胞ｄｎａにおけるマイクロサテライト不安定性の検出
|
|
GB201815041D0
(en)
|
2018-09-14 |
2018-10-31 |
Scancell Ltd |
Epitopes
|
|
US11945850B2
(en)
|
2018-09-17 |
2024-04-02 |
Immatics Biotechnologies Gmbh |
B*44 restricted peptides for use in immunotherapy against cancers and related methods
|
|
KR20210063362A
(ko)
|
2018-09-21 |
2021-06-01 |
버클리 라잇츠, 인크. |
작용화된 웰 플레이트, 이의 제조 및 사용 방법
|
|
BR112021005702A8
(pt)
|
2018-09-27 |
2022-11-08 |
Vaccibody As |
Método para selecionar neoepítopos
|
|
WO2020081875A1
(en)
|
2018-10-18 |
2020-04-23 |
Berkeley Lights, Inc. |
Proto-antigen-presenting synthetic surfaces, activated t cells, and uses thereof
|
|
KR20210090650A
(ko)
|
2018-11-07 |
2021-07-20 |
그릿스톤 바이오, 인코포레이티드 |
알파바이러스 신생항원 벡터 및 인터페론 억제제
|
|
JP7863702B2
(ja)
|
2018-11-08 |
2026-05-22 |
セルキュア インコーポレイテッド |
表現型特性が向上したｔ細胞組成物
|
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
CN109706065A
(zh)
*
|
2018-12-29 |
2019-05-03 |
深圳裕策生物科技有限公司 |
肿瘤新生抗原负荷检测装置及存储介质
|
|
JP2022521738A
(ja)
|
2019-02-20 |
2022-04-12 |
ルビウス セラピューティクス， インコーポレイテッド |
負荷可能な抗原提示ポリペプチドを含む操作された赤血球系細胞および使用方法
|
|
CN111621564B
(zh)
*
|
2019-02-28 |
2022-03-25 |
武汉大学 |
一种鉴定有效肿瘤新抗原的方法
|
|
US12427195B1
(en)
*
|
2019-03-11 |
2025-09-30 |
La Jolla Institute For Immunology |
Methods of neoantigen identification
|
|
US20220130489A1
(en)
*
|
2019-03-12 |
2022-04-28 |
Syntekabio,Inc. |
System and method for providing neoantigen immunotherapy information by using artificial-intelligence-model-based molecular dynamics big data
|
|
WO2020227233A2
(en)
*
|
2019-05-03 |
2020-11-12 |
Richard Guilhem |
Neoantigens in cancer
|
|
EP3966323A4
(en)
*
|
2019-05-06 |
2024-04-24 |
The Regents Of The University Of Michigan |
Targeted therapy
|
|
TWI867324B
(zh)
|
2019-05-08 |
2024-12-21 |
美商百歐恩泰美國公司 |
T細胞製備組合物及方法
|
|
CN112011833B
(zh)
*
|
2019-05-30 |
2024-04-26 |
上海桀蒙生物技术有限公司 |
筛选和分离肿瘤新生抗原的方法
|
|
SG11202113187WA
(en)
|
2019-05-30 |
2021-12-30 |
Gritstone Bio Inc |
Modified adenoviruses
|
|
CN110322925B
(zh)
*
|
2019-07-18 |
2021-09-03 |
杭州纽安津生物科技有限公司 |
一种预测融合基因产生新生抗原的方法
|
|
CN110706747B
(zh)
*
|
2019-09-17 |
2021-09-07 |
北京橡鑫生物科技有限公司 |
检测肿瘤新生抗原多肽的方法和装置
|
|
EP4038222A4
(en)
|
2019-10-02 |
2023-10-18 |
Arizona Board of Regents on behalf of Arizona State University |
Methods and compositions for identifying neoantigens for use in treating and preventing cancer
|
|
JP2023521662A
(ja)
|
2020-04-03 |
2023-05-25 |
グリットストーン バイオ インコーポレイテッド |
感染症抗原及びワクチン
|
|
US11920202B2
(en)
|
2020-04-09 |
2024-03-05 |
University Of Connecticut |
Unbiased identification of tumor rejection mediating neoepitopes
|
|
WO2021205027A1
(en)
|
2020-04-09 |
2021-10-14 |
Vaccibody As |
Individualized therapeutic anticancer vaccine
|
|
KR20230009426A
(ko)
*
|
2020-05-12 |
2023-01-17 |
스미토모 파마 가부시키가이샤 |
암을 처치하기 위한 의약 조성물
|
|
EP4149952A1
(en)
*
|
2020-05-12 |
2023-03-22 |
Institut Curie |
Neoantigenic epitopes associated with sf3b1 mutations
|
|
US20230210968A1
(en)
|
2020-06-11 |
2023-07-06 |
Massachusetts Institute Of Technology |
Ribonucleoprotein approach to boost the sting signaling for cancer immunotherapy
|
|
IL300026A
(en)
|
2020-08-06 |
2023-03-01 |
Gritstone Bio Inc |
Multiepitope vaccine cassettes
|
|
JP2023539056A
(ja)
|
2020-08-13 |
2023-09-13 |
ビオンテック ユーエス インコーポレイテッド |
Ｔ細胞を製造する組成物および方法
|
|
US20230323431A1
(en)
*
|
2020-08-31 |
2023-10-12 |
World Biotech Regenerative Medical Group Limited |
Personalized Immunogenic Compositions and Methods for Producing and Using Same
|
|
KR102552632B1
(ko)
*
|
2020-11-06 |
2023-07-06 |
사회복지법인 삼성생명공익재단 |
중추신경계 림프종을 진단하기 위한 마커, 이를 포함하는 중추신경계 림프종 진단 키트 및 중추신경계 림프종을 진단하는 방법
|
|
JP2024512462A
(ja)
*
|
2021-03-15 |
2024-03-19 |
アマゾン テクノロジーズ インコーポレイテッド |
不均一な悪性腫瘍についての腫瘍ワクチン抗原カバレッジを最適化するための方法
|
|
US20240240259A1
(en)
*
|
2021-03-26 |
2024-07-18 |
The Translational Genomics Research Institute |
Methods and compounds for neoantigen vaccines
|
|
BR112023022485A2
(pt)
|
2021-04-30 |
2024-01-09 |
Centre Hospitalier Univ Vaudois Chuv |
Expansão de linfócitos em um único recipiente
|
|
EP4346884A1
(en)
*
|
2021-05-27 |
2024-04-10 |
Amazon Technologies, Inc. |
Multicomponent chemical composition of a peptide-based neoantigen vaccine
|
|
AU2021461416A1
(en)
|
2021-08-24 |
2024-02-22 |
BioNTech SE |
In vitro transcription technologies
|
|
CN115772564B
(zh)
*
|
2021-09-08 |
2023-08-18 |
广州市基准医疗有限责任公司 |
用于辅助检测肺癌体细胞atm基因融合突变的甲基化生物标记物及其应用
|
|
EP4419716A1
(en)
*
|
2021-10-21 |
2024-08-28 |
CureVac Netherlands B.V. |
Cancer neoantigens
|
|
CN116287158A
(zh)
*
|
2021-12-08 |
2023-06-23 |
初源海生物科技(深圳)有限公司 |
一种新抗原鉴定和疗效预测方法
|
|
EP4493212A1
(en)
|
2022-03-14 |
2025-01-22 |
Generation Bio Co. |
Heterologous prime boost vaccine compositions and methods of use
|
|
EP4598949A1
(en)
|
2022-10-07 |
2025-08-13 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
|
|
WO2024083345A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Methods and uses associated with liquid compositions
|
|
AU2023367780A1
(en)
|
2022-10-25 |
2025-03-27 |
Barinthus Biotherapeutics North America, Inc. |
Self-assembling nanoparticles
|
|
AU2023372974A1
(en)
|
2022-11-02 |
2025-06-12 |
Centre Hospitalier Universitaire Vaudois (Chuv) |
Expansion of lymphocytes
|
|
US12531162B1
(en)
*
|
2023-05-31 |
2026-01-20 |
Northeastern University |
Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
|
|
EP4474016A1
(en)
|
2023-06-07 |
2024-12-11 |
Julius-Maximilians-Universität Würzburg |
Strategies to target extracellularly accessible ras protein
|
|
WO2024261339A1
(en)
|
2023-06-23 |
2024-12-26 |
Tigen Pharma Sa |
Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations
|
|
US12562256B2
(en)
*
|
2023-11-07 |
2026-02-24 |
New York University |
Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy
|
|
WO2025202937A1
(en)
|
2024-03-26 |
2025-10-02 |
BioNTech SE |
Cancer vaccines
|
|
WO2026097062A1
(en)
|
2024-11-04 |
2026-05-07 |
Dana-Farber Cancer Institute, Inc. |
Genomic profiling of cells to monitor minimum residual disease
|
|
WO2026159255A1
(en)
|
2025-01-24 |
2026-07-30 |
BioNTech SE |
Technologies for mutation detection using tumor modeling and feedback
|